Education
About Us
Working with TipRanks
Follow Us
Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
Total Valuation
Olema Pharmaceuticals has a market cap or net worth of $576.74M. The enterprise value is $514.84M.
Market Cap$576.74M
Enterprise Value$514.84M
Share Statistics
Olema Pharmaceuticals has 68,659,920 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding68,659,920
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Olema Pharmaceuticals’s return on equity (ROE) is -0.32 and return on invested capital (ROIC) is -34.66%.
Return on Equity (ROE)-0.32
Return on Assets (ROA)-0.29
Return on Invested Capital (ROIC)-34.66%
Return on Capital Employed (ROCE)-0.35
Revenue Per Employee0.00
Profits Per Employee-1.35M
Employee Count96
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Olema Pharmaceuticals is ―. Olema Pharmaceuticals’s PEG ratio is -0.94.
PE Ratio―
PS Ratio0.00
PB Ratio0.84
Price to Fair Value0.84
Price to FCF-3.28
Price to Operating Cash Flow-5.24
PEG Ratio-0.94
Income Statement
In the last 12 months, Olema Pharmaceuticals had revenue of 0.00 and earned -129.47M in profits. Earnings per share was -2.20.
Revenue0.00
Gross Profit0.00
Operating Income-142.26M
Pretax Income-129.47M
Net Income-129.47M
EBITDA-141.87M
Earnings Per Share (EPS)-2.20
Cash Flow
In the last 12 months, operating cash flow was -134.67M and capital expenditures 0.00, giving a free cash flow of -134.67M billion.
Operating Cash Flow-134.67M
Free Cash Flow-134.67M
Free Cash Flow per Share-1.96
Dividends & Yields
Olema Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.66
52-Week Price Change143.24%
50-Day Moving Average9.19
200-Day Moving Average5.88
Relative Strength Index (RSI)87.52
Average Volume (3m)1.28M
Important Dates
Olema Pharmaceuticals upcoming earnings date is Mar 2, 2026, After Close (Confirmed).
Last Earnings DateNov 11, 2025
Next Earnings DateMar 2, 2026
Ex-Dividend Date―
Financial Position
Olema Pharmaceuticals as a current ratio of 10.50, with Debt / Equity ratio of 0.48%
Current Ratio10.50
Quick Ratio10.50
Debt to Market Cap0.00
Net Debt to EBITDA0.97
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Olema Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Olema Pharmaceuticals EV to EBITDA ratio is -1.44, with an EV/FCF ratio of -1.96.
EV to Sales0.00
EV to EBITDA-1.44
EV to Free Cash Flow-1.96
EV to Operating Cash Flow-1.96
Balance Sheet
Olema Pharmaceuticals has $328.96M in cash and marketable securities with $4.48M in debt, giving a net cash position of $324.48M billion.
Cash & Marketable Securities$328.96M
Total Debt$4.48M
Net Cash$324.48M
Net Cash Per Share$4.73
Tangible Book Value Per Share$6.95
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Olema Pharmaceuticals is $34.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$34.40
Price Target Upside303.76% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast17.23%